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Adaptive responses to very low protein diets: The first comparison of
ketoacids to essential amino acids. Eight patients with chronic renal
failure (GFR 18.8 2.7 mI/mm) were randomized to a crossover
comparison of a very low protein diet (VLPD) containing 0,28 g protein
and 35 kcal per kg per day, plus an isomolar mixture of either ketoacids
(KA) or essential amino acids (EAA). Subjects initiated the diets 14
days before hospital admission and following a four-day equilibration, a
five-day nitrogen balance (BN) was performed. Whole-body protein
turnover (WBPT) was measured during fasting and feeding using
intravenous [l)3C]leucine and intragastric [5,5,5-2H3]leucine. Even
though the VLPD/KA regimen contained 15% tess nitrogen, BN was
neutral and did not differ between the regimens. Nitrogen conservation
with KA was due to a reduction in urea nitrogen appearance. Rates of
WBPT measured during fasting and feeding did not differ between the
KA or EAA regimens. During both regimens, feeding decreased protein
degradation, whereas protein synthesis was unchanged. Although feed-
ing stimulated leucine oxidation, rates were 50 to 100% lower than
reported in CRF patients consuming 0.6 or 1.0 g protein/kg/day. Thus,
neutral BN with the VLPD regimen is achieved by a marked reduction
in amino acid oxidation and a postprandial inhibition of protein degra-
dation.
When dietary protein intake exceeds the daily requirement,
the excess amino acids are catabolized and the nitrogen ex-
creted, primarily in the form of urea [1]. In the presence of
progressive renal insufficiency, waste nitrogen will accumulate,
eventually resulting in symptomatic uremia. In order to limit the
accumulation of nitrogenous waste products, and in the hope of
slowing the progression of renal failure, dietary protein restric-
tion has been recommended for patients with moderate to
severe chronic renal failure (CRF) [21.
Two dietary regimens have been used to treat patients with
CRF: (1) the conventional low protein diet (LPD) providing
'—0.6 g protein/kg/day; or (2) a very low protein diet (VLPD)
providing —0.3 g protein/kg/day, supplemented with essential
amino acids (EAA), or their nitrogen-free ketoanalogs (KA).
Prospective randomized trials have suggested that the conven-
tional LPD may slow the rate of progression when compared to
an unrestricted diet [3, 4]. Also, recent evidence indicates that
when CRF patients consumed a VLPD alternatively supple-
mented with KA or EAA, progression was significantly slower
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with KA [5]. Although these studies suggest that dietary protein
restriction may slow progression, some controversy still exists
regarding the nutritional adequacy of these regimens. For
instance, early studies indicated that the conventional LPD
yielded neutral nitrogen balance (BN) in CRF patients [61, yet
other investigators have not confirmed this finding [7]. Simi-
larly, the VLPD regimens has been reported to produce neutral
[8, 9] or negative BN [10, 11] in CRF patients.
Negative BN in response to these dietary regimens could be
due to the fact that the diet was nutritional inadequate, or
because patients with CRF were unable to activate compensa-
tory mechanisms leading to nitrogen conservation when dietary
protein was restricted. In normal man, successful adaptation to
dietary protein restriction involves a reduction in the rate of
amino acid oxidation leading to more efficient use of dietary
amino acids and the reutilization of amino acids liberated from
endogenous protein breakdown. In this case, urea production is
decreased. There can also be concomitant changes in whole-
body protein synthesis and degradation (that is, protein turn-
over) that will determine whether the patient is in nitrogen
balance [12]. Interestingly, Goodship et al demonstrated that
the adaptive responses to dietary protein restriction in nonaci-
dotic CRF patients were similar to those of control subjects
consuming the conventional LPD [7]; however both normal
subjects and CRF patients were in negative BN, suggesting that
this regimen was inadequate, at least during the short-term.
In spite of several studies comparing VLPD diets supple-
mented with EAA or KA [5, 13—20], the adaptive responses to
the VLPD regimen have not been reported. This is of interest
because the essential amino acid, leucine, and its ketoacid,
a-ketoisocaproate, have been suggested to promote protein
anabolism in vivo [2 1—241. On the other hand, a-ketoisocaproate
could increase amino acid requirements by stimulating the
activity of the rate-limiting enzyme for branched-chain amino
acid oxidation, branched-chain ketoacid dehyrogenase [25].
To determine whether there is any nutritional advantage to
using a supplement of ketoacids or essential amino acids with
the VLPD regimen, we performed a randomized crossover
comparison of a VLPD containing 0.28 g protein/kg/day, sup-
plemented with an isomolar mixture of KA or EAA. Dietary
adequacy was determined by monitoring changes in serum
proteins, anthropometrics, and nitrogen balance, as well as by
measuring rates of whole-body protein synthesis, protein deg-
radation, and leucine oxidation during fasting and feeding.
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Methods
Patients
Eight adult subjects (5 women and 3 men; age 50 3, range
38 to 65 years) with chronic renal failure were enrolled. Primary
renal diagnoses included idiopathic glomerulonephritis (4),
polycystic kidney disease (3), and unknown (1). No patient had
an acute intercurrent illness, diabetes mellitus, malnutrition, or
obesity [that is, <80% or >120% standard body weight (SBW),
respectively] [261. Antihypertensive and antihyperlipidemic
medications were prescribed as required, and metabolic acido-
sis corrected (serum HCO3  25 mM) with supplemental
NaHCO3 when necessary. Each patient also received ferrous
sulfate 325 mg daily, a water-soluble multivitamin (Nephro-
capTM, Fleming Co., Fenton, Missouri, USA), and CaCO3 (1 g
elemental calcium/day). This protocol was approved by the
Human Investigations Committee at Emory University and a
written informed consent was obtained from each participant.
Materials
L-[1-'3C} leucine (99 mol% 13C), L-[5,5,5-2H3] leucine (99
mol% 2H3), and sodium-[13C] bicarbonate (99 mol% 13C) were
obtained from Tracer Technologies Inc. (Somerville, Massa-
chusetts, USA). Each labeled compound was determined to be
sterile and pyrogen-free prior to use (Findley Research Inc.,
Fall River, Massachusetts, USA). '5I-Iothalamate (Glofil) was
purchased from Isotex Diagnostics (Friendswood, Texas, USA)
and the radioactivity of plasma and urine samples measured
using a Beckman 5500B gamma counter (Beckman Instruments
Inc., Fullerton, California, USA). A calibrated pump (Model
22, Harvard Apparatus Inc., Southnatick, Massachusetts,
USA) was used to infuse L-[1-'3C] leucine. Breath samples
were collected using a latex balloon with a one way valve,
(USAT; Rancho Cucamonga, California, USA), transferred to
15-mI non-silicon coated, evacuated glass tubes (Venoject
T-218U; Terumo Medical, Elkton, Maryland, USA) and stored
at room temperature until analyzed for 'CO2 enrichment. Total
CO2 production was determined by indirect calorimetry using a
DeltatracTM Metabolic monitor (Sensormedics; Anaheim, Cali-
fornia, USA). Serum chemistries and transferrin were per-
formed by the Emory University Hospital Clinical Chemistry
Laboratory using an Olympus AV 5000 autoanalyzer (Olympus
Corp., Lake Success, New York, USA) and Beckman Array-
Protein System (Beckman Instruments Inc., La Brea, Califor-
nia, USA), respectively.
Composition of supplements
The essential amino acid (EAA) and ketoacid-amino acid
(KA) supplements were provided by Ross Laboratories (Co-
lumbus, Ohio, USA) and were ingested in three equals portions
with meals. The KA supplement was given in a dose of 2.8 g/l0
kg SBW (290.2 mg N and 20.24 mmol per 2.8 g KA), whereas
the isomolar EAA mixture provided 3.29 g/10 kg SBW (424.7
mg N and 20.04 mmol per 3.29 g EAA).
The KA supplement is similar in composition to mixture
"EE" used by Mitch et al [27] and provides the ketoacids as
their basic amino acid salts. Each gram of the ketoacid-amino
acid mixture contained: L-lysine R,S--keto-B-methlyvalerate
(234.1 mg); L-ornithine c-ketoisovalerate (225.3 mg); L-orni-
thine a-ketoisocaproate (222.2 mg); L-histidine a-ketoisoca-
proate (69.1 mg); calcium D,L-a-hydroxy-y-methylthiobutyrate
(20.5 mg); L-tryptophan (3.0 mg); L-threonine (50.5 mg); and
L-tyrosine (175.4 mg). Each gram of the EAA mixture pro-
vided: L-leucine (120.9 mg); L-isoleucine (93.6 mg); L-valine
(87.5 mg); L-lysine acetate (148.6 mg); L-histidine (31.3 mg);
L-tryptophan (2.7 mg); L-methionine (15.8 mg); L-threonine
(41.3 mg); L-tyrosine (148.6 mg); and L-ornithine monohydro-
chloride (253.5 mg). Since L-ornithine was provided as the
chloride salt, patients were given supplemental NaHCO3 while
consuming the EAA supplement.
Study protocol
All participants received intensive nutritional counseling
from a dietitian familiar with the design, implementation and
nutritional assessment of patients consuming protein restricted
diets. Subjects were initially instructed in a conventional low-
protein diet (LPD) containing 0.6 g protein/kg/day, 35 kcallkg/
day, s10 mg/kg/day P04, and 2 to 4 g sodium. We chose to
initially treat all patients with the conventional LPD because:
(1) compliance with the VLPD regimen is enhanced by the
knowledge base obtained by mastering the less restrictive LPD
regimen; and (2) it ensured that all participants consumed an
identical "lead-in diet".
Outpatient dietary compliance was assessed by analyzing
three-day dietary diaries and the 24-hour urinary urea nitrogen
excretion (UUN) [281. if nitrogen balance (BN) is assumed to be
neutral, protein intake can be estimated from the 24-hour UUN
plus an estimate for non-urea nitrogen (NUN) losses as 0.03 1 g
N/kg body weight/day [1]. Following confirmation of compli-
ance with the LPD regimen (± 20% of prescribed protein intake
estimated from the 24 hr UUN + 0.031 g N/kg), patients were
instructed in a very low protein diet (VLPD) containing 0.28 g
protein/kg/day, 35 kcal/kg/day,  10 mg/kg/day P04 and 2 to 4 g
sodium.
Patients were then randomized to receive the essential amino
acid (EAA) or ketoacid-amino acid mixture (KA) and instructed
to initiate the VLPD regimen plus the assigned supplement, 14
days prior to their scheduled admission to the Emory Univer-
sity Hospital Clinical Research Center (CRC). The 10-day CRC
protocol is illustrated in Figure 1. Following a four-day equili-
bration period, a five-day nitrogen balance was performed. A
complete blood count, serum chemistries, and anthropometrics
were measured on days 2 and 9, and a serum urea nitrogen
(SUN) was obtained each morning. On day 2, the '251-lothala-
mate clearance was measured, and on day 3 the fractional
recovery of '3CO2 was measured during an infusion of
NaH'3C03. Since the natural background '3C02 enrichment of
expired air may change during feeding, a "sham infusion" was
performed on day 9. Finally, leucine turnover was performed
during fasting and feeding on day 10.
Following the initial 10-day CRC admission (Phase 1), pa-
tients were discharged and instructed to resume the conven-
tional LPD for  four week "wash-out" period. Fourteen days
prior to readmission (Phase 2) participants resumed the VLPD
diet plus the alternative supplement, and were then admitted for
an identical CRC protocol to that previously described.
lothalamate clearance
During each CRC admission, the glomerular filtration rate
was measured from the renal clearance of '251-Iothalamate
Ic--4 day Iead-in-->I<--5 day nitrogen baance-->I
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The 10-day inpatient protocol evaluating the metabolic re-
to a very low protein diet (VLPD) supplemented with either
/ amino acids (EAA) or a ketoacid-amino acid mixture (KA).
following an overnight fast [291. Following a 60- to 90-minute
equilibration period four consecutive, timed (30 mm) urine
collections were obtained. Plasma radioactivity was determined
from the log mean of the bracketing values obtained at the
beginning and end of each clearance period, and the GFR
calculated as the mean of the four clearance periods.
Nitrogen balance
A five-day nitrogen balance was performed during each CRC
admission. During each balance period, daily 24-hour urine
collections were analyzed for total nitrogen, creatinine, and
urea, and the pooled five-day stool collection analyzed for total
nitrogen [1]. The nitrogen content of food, urine and feces was
determined using the micro-Kjeldahl method and urinary urea
nitrogen measured fluorometrically [30].
Nitrogen balance (BN) was calculated as nitrogen intake (IN)
minus urinary nitrogen appearance (U) minus non-urea nitrogen
(NUN): BN =I — U — NUN. Nitrogen intake was determined
by duplicate diet analysis and was corrected for uneaten food or
emesis. Urea nitrogen appearance (U) was calculated as the
algebraic sum of the mean UUN excretion rate, plus the daily
change in the urea nitrogen pool. The urea pool was calculated
from the volume of distribution (VD) of urea, and daily mea-
surements of body weight and serum urea nitrogen. The V of
urea was estimated as 60% of body weight since we have shown
that estimated values of urea appearance are indistinguishable
from those determined by directly measuring the VD of urea
with '4C-urea [1]. The rate of change of the urea pool was
determined from the linear regression of urea pool and time
over the period of observation [31]. Non-urea urinary nitrogen
was calculated as total urinary nitrogen minus urinary urea
nitrogen, that is, NUUN TUN — UUN. NUN was then
calculated as the sum of NUUN plus the nitrogen lost in feces
(FN); that is, NUN = NUUN + FN [11.
Tracer infusion studies
Sham infusion. The contribution of the formula meal to
background '3C02 enrichment was quantitated by collecting
expired breath samples during a sham infusion without tracers,
using an identical protocol to that described for the leucine
turnover. Since foods with a low natural '3C abundance were
deliberately chosen for the formula meal [32], and since feeding
stimulated total CO2 production to a greater extent than the
measured increase in [l-'3C] leucine oxidation, we found that
the enrichment of expired 13C02 actually decreased during the
feeding protocol. Therefore, to avoid underestimating '3C02
enrichment derived from the oxidation of [1-'3C] leucine during
feeding (and hence feeding leucine oxidation rates), the plateau
'3C02 enrichment measured during the leucine turnover was
corrected for background enrichment by subtracting the steady-
state '3C02 enrichment measured during the feeding phase of
the sham infusion.
Bicarbonate kinetic. When NaH'3C03 or [l-'3C]leucine is
infused, a fraction of the labeled carbon liberated from the
infused tracer is not recovered from expired air as 13C0,. The
portion retained in the body is believed to represent CO2
fixation in metabolic pathways or loss to slowly exchanging
pools [33, 341. Since the retained fraction has not been reported
in patients with renal failure, the fractional recovery of '3C02
was measured during an infusion of NaH'3C03, using an
identical protocol to that described for the leucine turnover.
Following an overnight fast, breath samples were collected at
7:30 a.m. and 7:45 a.m. for determination of background 13C02
enrichment. At 8:00 a.m., a priming dose of NaH13CO3 (5.4
smo1 kg) was given followed by a 10 hour infusion of
NaH'3C03 (3.9 mol kg hC1). During the last six hours of
the NaH'3CO3 infusion, (12 noon to 6 p.m.), small, isocaloric,
isonitrogenous liquid meals providing of the day's intake of
protein and calories (that is, 0.14 g protein and 17.5 kcal per kg
SBW) were given in equal portions at 30 minute intervals. At 10
a.m. and 3 p.m., CO2 production was measured over 30 minutes
by indirect calorimetry. Between 11 a.m. to 12p.m., and 5 to 6
p.m., breath samples were collected at 15 minute intervals for
measurement of 13C02 enrichment during fasting and feeding.
The fraction of infused ['3C]bicarbonate recovered as '3C02 in
expired air was calculated as:
FR = F'3co,/iNaH'3C03 (1)
where F'302, is the '3C02 recovered in expired air
(mo1 kg' hr'), and iNaH'3CO3 is the '3C sodium bicar-
bonate infusion rate (mol kg1 hr') [33].
Seven of the eight participants (3 men, 4 women) underwent
the NaH'3C03 infusion protocol. To correct for '3CO2 recov-
ery, the individual leucine oxidation rates were divided by the
mean fractional recovery (that is, 0.73 0.02 vs. 0.77 0.02;
fasting vs. feeding, respectively).
Leucine kinetics. Leucine turnover was performed on day 10
following an overnight fast (Fig. 2). On the morning of the
leucine infusion, a superficial hand vein was cannulated in a
retrograde direction and the hand placed in a temperature
controlled "hot box" (58 to 60°C) for blood sampling [351. An
intravenous catheter was then inserted antegrade into the
contralateral forearm for isotope infusion. Baseline blood and
breath samples were collected at 7:30 a.m. and 7:45 a.m. for
determination of background '3C enrichment of plasma leucine,
a-KIC, and expired CO2. At 8:00 a.m., a priming dose of
Na'3HC03 (0.11 mg/kg) and L-[l-13C]leucine (2.0 mol kg')
was given, followed by a constant infusion of [l-13C]leucine (4.2
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Fig. 2. The leucine turnover protocol entailed a 10 hour (8 a.m. to 6
p.m.) intravenous infusion of L-[1-'3C]leucine with sampling of blood
and expired air at isotopic steady-state. Patients fasted until 12 p.m.
and then received '/2 theirdaily intake of protein and calories (excluding
the supplement) as isonitrogenous, isocaloric feedings (supplemented
with [5,5,5,2D31 leucine) at 30 minute intervals throughout the afternoon
(12 p.m. to 6 p.m.).
.Lmol - kg1 - hr') over 10 hours. During the last six hours of
the infusion (12 p.m. to 6 p.m.), an isocaloric, isonitrogenous
liquid meal (supplemented with [5,5,5-2H3] leucine) represent-
ing ¼ of the day's intake of protein and calories was given in
equal portions at 30 minutes intervals to study the responses to
feeding. At 10 a.m. and 3 p.m., CO2 production was measured
over 30 minutes by indirect calorimetry. While at isotopic
steady-state, blood and expired breath were sampled every 15
minutes between 11 a.m. to 12 p.m. and 5 to 6p.m.
Calculations. Whole-body leucine turnover was measured
during fasting and feeding using standard formulae and plasma
leucine (primary pool model) and plasma a-KIC (reciprocal
pooi model) enrichment [36, 37]. Although the conclusions were
identical using either model, data are presented using plasma
a-KIC enrichment, since it has been suggested to more closely
approximate the average whole-body intracellular enrichment
for leucine [38, 39].
Leucine flux (Q) was calculated from the dilution of infused
[l-'3C]leucine at isotopic steady-state (smol kg1 hr'):
Q = i[E1/E — 1]
where i is the [1-'3C] leucine infusion rate (smol kg' -hr');
E1, is the infusate [1-13C]leucine enrichment (atoms % excess);
and E, is the plasma [1-'3C]leucine or [l-'3C] a-KIC enrich-
ment at isotopic plateau (atoms % excess).
The rate of '3C02 released (mol kg' hC') from the
catabolism of [l-13C} leucine is:
F'3co2 = Fc02 X E0/W[6O X 44.6/100 X FR]
where F0, is the CO2 production rate (cm3 - min '); E0,, the
13C02 enrichment in expired air at isotopic steady state (atoms
% excess); and W, the subject's weight (kg). The constants 60
mm . hr and 44.6 smol cm3 (at STP) convert F02 to
jsmol hr1; the factor 100 converts atoms % excess to a
fraction; and FR is the fraction of 13C02 released from the
oxidation of [1-'3C]leucine which is recovered in expired air.
During the fasting period, background '3C02 enrichment was
assumed to be same as that measured just prior to initiating the
tracer infusion. For the feeding phase, the average
enrichments obtained during the last hour of the sham infusion
were used as the baseline.
Therefore, the rate of leucine oxidation (C) (mol -kg'
hr) is:
C = F'3co2[1/E — l/E1] X 100 (4)
from which the rate of leucine incorporation into protein can be
calculated as:
S=Q—C (5)
The rate of leucine appearance from protein (B) is the
difference between leucine flux (Q) and dietary leucine intake
(I):
B=Q—I. (6)
When subjects are studied in the postabsorptive state, I = 0,
and the total rate of appearance (Q)of leucine into the plasma
compartment (jsmol - kg' hr 1) is equivalent to endogenous
leucine appearance (B), and hence is an index of net proteoly-
sis.
In the fed state, dietary amino acids must pass through the
splanchnic bed where some amino acids may be removed.
Failure to account for splanchnic removal of dietary leucine
would result in an underestimation of the rate of protein
breakdown (B) during feeding [40]. Whether uremia or dietary
protein restriction influence splanchnic leucine metabolism is
unknown.
To estimate leucine removal by the splanchnic bed, [5,5,5
2H3] leucine was added to the liquid formula and the contribu-
tion of dietary leucine to plasma leucine enrichment measured
directly [41]. The total leucine content of the meal was calcu-
lated by summing the formula leucine content (Diet Planner
Version 2.03, UCSF Clinical Study Center, San Francisco
General Hospital), plus the [2H3] leucine added to the formula.
The enrichment of [2H3] leucine in the meal was then calculated
by dividing the [2H3] leucine content by the total leucine
content. Since the [2H3] leucine enrichment of the formula was
known and the plasma [2H3] leucine enrichment was measured,
the fraction of circulating leucine derived from the meal was
(2) calculated as follows:
Fm = Ep[2H31/Ed[2H3] (7)
where Fm is the fraction of plasma leucine from meal; E[2H3],
equals the plasma [2H3] leucine enrichment; and Ed[2H3], is the
dietary [2H3] leucine enrichment.
Knowing the fraction of the circulating leucine derived from
the meal (Fm) and total leucine flux (Q), the rate of dietary
(3) leucine entry (I) can be calculated:
IFmXQ (8)
Finally, knowing the rate of total leucine flux (Q) and the
fraction of circulating leucine derived from the diet, leucine
derived from endogenous protein breakdown could be calcu-
lated as, B = Q — I [41].
Analytical methods
Infusate and plasma amino acid concentrations. Infusate and
plasma amino acid concentrations were measured by ion-
exchange chromatography using an amino acid analyzer (Model
334; Beckman Instruments, Fullerton, California, USA).
Mass spectrometry analysis. All GC/MS analyses were per-
formed using a DB-130l capillary column (J & W, Folsom,
* * * * *
* * * * *
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California, USA) and a Hewlett Packard 5890 Series II gas
chromatograph coupled to a HP5988A quadrapole mass spec-
trometer (Hewlett-Packard Corp., Cupertino, California,
USA). For the measurement of the '3C and 2H leucine enrich-
ments, 200 .d of plasma was extracted using the method of
Adams [42], and the T-butyldimethylsilyl derivative prepared
according to Chaves das Nares and Vasconcelos [43]. Isotopic
enrichments were then determined by selected ion monitoring
[M-57] at m/z 302, 303, and 305 corresponding to natural
leucine, [1-'3C]leucine, and [2H3]leucine, respectively. Mea-
surement of the isotope enrichment of plasma a-KIC was
performed using the extraction and quinoxalinol derivatization
procedures of Rocchicchioli, Leroux and Carter [44]. The
quinoxalinol-t-butyldimethysilyl derivative was then prepared
according to the method of Langebeck, Luthe and Schaper [45]
and analyzed by selected ion monitoring [M-57] at m/z 259,
260, 262 corresponding to natural a-KIC, [13C]a-KIC, and
[2H3]a-KIC, respectively. All isotopic enrichments were mea-
sured against calibration standards and are expressed as the
mole fraction above baseline.
content in expired air. The 13C02 enrichment of
expired air was measured using the a Finnegan Model delta E
gas isotope-ratio mass spectrometer system as previously de-
scribed [36].
Plasma hormones levels. Blood samples for determination of
hormone concentration were obtained at isotopic steady-state
during fasting and feeding (Fig. 2). Plasma insulin, growth
hormone (IncStar Corporation, Stillwater, Minnesota, USA),
and glucagon (Radioassay Systems Laboratory Inc., Carson,
California, USA) were measured by radioimmunoassay and
cortisol by a competitive protein binding radioimmunoassay
(Becton Dickinson Immunodiagnostics, Orangeburg, New
York, USA).
Statistics
Values are reported as mean SE. A two-period crossover
model consisting of sequence, subject nested within sequence,
diet, period, and mean square error was used to compare results
between the VLPD/KA and VLPD/EAA regimens (SAS Insti-
tute, Inc., Cary, North Carolina, USA). Because the leucine
turnover results, as well as the plasma hormones and amino
acid concentrations were measured during fasting and feeding,
the response to feeding was also analyzed using the crossover
model. To determine whether the response to treatment was
dependent upon the order of diet administration, all outcome
variables were initially tested for a sequence effect. The cross-
over model was used to test for differences between the two
dietary regimens only when the sequence effect was not de-
tected. Alternatively, if a sequence effect was observed, the
two dietary regimens were compared using the Period 1 data
only. Within group (such as fasting vs. feeding) comparisons
were analyzed using the paired 1-test (two-tailed). Treatment
and period effects were considered significant at P 0.05;
sequence effects were considered significant at P  0.10.
To determine whether there was an independent effect of
GFR on nitrogen balance or rates of whole-body protein turn-
over between diets, we performed an analysis of covariance
(ANCOVA). A two-way analysis of variance (ANOVA) was
used to compare leucine oxidation rates measured during
fasting and feeding in CRF patients consuming 0.3, 0.6 or 1.0 g
Table 1. Characteristics of the patient population
VLPD/KA VLPD/EAA
Weight kg 67.0 3.2 66.7 3.1
Caloric intake kcal/kg/day 34.8 0.1 34.5 0.3
Dietary protein glday 20.5 1.2 20.5 1.2
N content supplement glday 2.1 0,1 3.0 0.Ia
Serum albumin gIdi 3.7 0.1 3.7 0.1
Serum transferrin mg/dI 238 15 231 16
Serum HCO3 mmol/liter 27 1 27 1
lothalamate clearance mi/mm 16.5 2.1 18.5 3.5
Abbreviations are: VLPD, very low protein diet; KA, ketoacids;
EAA, essential amino acids. Values are mean SE.
a p < 0.0001; VLPD/KA vs. VLPD/EAA
protein/kg/day (Fig. 5), and post-hoc analyses were adjusted for
multiple comparisons using the Bonferroni procedure (Systat,
Inc.; Evanston, Illinois, USA).
Results
Clinical characteristics
Illustrated in Table I are selected clinical characteristics
measured while the patients consumed the very low protein diet
(VLPD) supplemented with either essential amino acids (EAA)
or the ketoacid-amino acid mixture (KA). By design, the
protein and calorie intake provided by the VLPD diet did not
differ during the two phases of the study. Since the KA and
EAA supplements were provided as isomolar mixtures, the
nitrogen content of the EAA supplement exceeded KA by 32%
(Table 1). Body weight, anthropometrics (data not shown), as
well as serum albumin and transferrin were indistinguishable
during the KA and EAA regimens, suggesting that the patients
nutritional status did not differ while patients consumed the two
diets. Finally, serum bicarbonate and iothalamate clearance
(GFR) did not differ with either regimen, excluding any con-
founding effect of acidosis or uremia on protein metabolism
(Table 1). With the VLPD/KA regimen, GFR ranged from 9.9 to
26.9 mI/mm (9.0 to 25.8 ml/min/1.73 m2) and 7.1 to 36.9 mI/mm
(6.5 to 34.5 ml/min/l .73 m2) with the VLPD/EAA regimen.
Nitrogen balance
Illustrated in Table 2 and Figure 3 are the nitrogen balance
(BN) data for the eight patients while they consumed the KA or
EAA regimens. Total nitrogen intake was 15% less with KA (P
< 0.0001), and this was associated with a corresponding 15%
decrease (P < 0.001) in total nitrogen excretion (Fig. 3). This
difference was due solely to a reduction in urea nitrogen
appearance with KA, since non-urea nitrogen excretion did not
differ between the two diets (Table 2). More importantly, even
though nitrogen intake was 15% lower with KA, nitrogen
balance remained positive and did not differ between the two
regimens (Table 2; Fig. 3). Even when corrected for unmea-
sured nitrogen losses estimated as 8 mg/kg/day [46], BN was
neutralwithbothdiets(0.12 0.25vs. 0.14 0.27gN/day; KA
vs. EAA, respectively).
Leucine kinetics
Whole-body leucine turnover was measured using intrave-
nous [l-'3C] leucine, and the contribution of dietary leucine to
total leucine flux estimated by supplementing the formula meal
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Table 2. Individual values for components of nitrogen balance in CRF patients consuming a very low protein diet supplemented with either
ketoacids or essential amino acids
'N UNA NUN FN BN
1 2 1 2 1 2 1 2 1 2
Patients g N/day
1
2
3
4
5
6
7
8
Mean
6.27 0.06
4.87 0.00
4.97 0.01
5.34 0.00
5.38 0.00
5.22 0.00
7.22 0.02
7.69 0.00
5.87 0.38
7.16 0.00
5.87 0.00
5.90 0.00
5.80 0.00
6.40 0.00
6.40 0.00
8.48 0.00
8.40 0.00
6.80 0.39'
3.92 0.22
3.64 0.14
2.71 0.12
2.55 0.14
3.69 0.29
3.75 0,13
3.62 0.09
3.43 0.13
3.41 0.18
4.76 0.27
3.89 0.16
3.42 0.12
3.96 0.11
3.72 0.09
5.29 0.31
4.45 0.10
4.42 0.09
4.24 0.21a
1.26 0.04 1.20 0.12
0.92 0.05 1.19 0.09
1.85 0.04 2.24 0.03
1.60 0.03 2.03 0.04
1.63 0.04 1.86 0.09
2.12 0.05 1.61 0.08
2.40 0.07 2.30 0.07
2.71 0.08 2.68 0.06
1.81 0.21 1.89 0.19
0.74 0.00
0.51 0.00
0.94 0.00
0.99 0.00
1.16 0.00
0.89 0.00
1.63 0.00
1.45 0.00
1.04 0.13
0.74 0.00
0.46 0.00
1.68 0.00
1.18 0.00
1.25 0.00
0.39 0.00
1.67 0.00
1.54 0.00
1.11 0.19
1.09 0.28
0.32 0.14
0.41 0.16
1.18 0.13
0.15 0.31
—0.65 0.14
1.20 0.12
1.54 0.18
0.66 0.26
1.21 0.12
0.79 0.23
0.24 0.11
—0.19 0.08
0.81 0.09
—0.49 0.31
1.74 0.16
1.29 0.14
0.67 0.27
Abbreviations are: 1, VLPD/KA, 2, VLPD/EAA; 'N' nitrogen intake; UNA, urea nitrogen appearance; NUN, non-urea nitrogen; FN, fecal
nitrogen; BN, nitrogen balance. Values are mean SE.
a F' < 0.005
b P < 0.0001; VLPD/ KA vs. VLPD/EAA
8
Output Balance
Fig. 3. Nitrogen intake, nitrogen output, and nitrogen balance mea-
sured while CRF patients consume a very low protein diet supple-
mented with EAA (black bars) or KA (white bars). Values are mean
SE (tP < 0.001, ¶P < 0.0001 KA vs. EAA).
with [5,5,5,2H3] leucine [41]. The splanchnic bed removed 27
6% and 31 6% of dietary leucine during the VLPD/KA and
VLPD/EAA protocols, respectively (P NS). Therefore, the
fraction of circulating leucine derived from the formula meal
was 19 1% and 18 2% during the VLPD/KA and VLPD/
EAA admissions (P = NS). Conversely, endogenous leucine
flux represented 81 to 82% of total leucine flux during feeding.
In both the postabsorptive and fed state, plasma [l-'3CJ KIC
enrichment and 13C02 enrichment in expired air were at isoto-
pic steady state when sampled (Fig. 4). During fasting, rates of
whole-body protein degradation, protein synthesis, and leucine
oxidation did not differ between the KA and EAA regimens
(Table 3). Likewise, in response to feeding there was no
difference in the rates of whole-body protein degradation,
synthesis or leucine oxidation between the two diets. The
metabolic responses to feeding can also be appreciated in Table
3. Feeding significantly decreased protein degradation during
both dietary regimens (P < 0.01, KA; P < 0.005, BAA). In
contrast, feeding did not alter rates of whole-body protein
synthesis. Finally, leucine oxidation increased during feeding
with both regimens (P < 0.001).
Plasma hormone and amino acid levels
Plasma hormone and branched-chain amino acid (BCAA)
levels were also measured during the leucine turnover protocol
(Tables 4 and 5). Similar to the whole-body protein turnover
results, plasma insulin, glucagon, cortisol, and growth hormone
levels did not differ between the KA or EAA regimens (Table
4). During both dietary regimens, insulin and glucagon levels
increased in response to feeding (P < 0.001), whereas plasma
cortisol and growth hormone did not change (Table 4). With the
exception that feeding plasma valine levels were higher with
EAA (P < 0.05), plasma BCAA levels did not differ between
dietary regimens (Table 5). In response to feeding, plasma
BCAA levels decreased significantly with both regimens.
Discussion
Our results indicate that a diet providing —0.28 g protein and
35 kcal per kg SBW per day, plus a supplement of either KA or
BAA maintains the nutritional status of CRF patients. More-
over, despite containing 15% less nitrogen, nitrogen balance
remained neutral with the VLPD/KA regimen, due to a de-
crease in urea appearance. Interestingly, the crossover model
utilized for statistical analysis revealed a sequence effect for
BN; that is, BN was significantly greater with both regimens in
the four patients who were randomized to receive KA first.
When the data was then analyzed using period 1 only, BN was
significantly more positive with KA (0.69 0.10 vs. —0.16
0.33 g N/day, KA vs. EAA respectively; P < 0.05). We have no
clear explanation for this finding. Presumably, an anabolic
response to KA would be reflected by an increase in protein
synthesis, a decrease in protein degradation, or both. However,
we did not detect any differences in the rates of whole-body
protein turnover between these two dietary regimens (Table 3).
We would also expect BN to be more positive with KA
regardless of which diet was given first. Again, our analyses
1
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Table 3. Whole-body leucine turnover measured in CRF patients consuming a VLPD supplemented with KA or EAA
Protein degradation Protein synthesis Oxidation
1 21 2 1 2
junol kg-I hr'
VLPD/KA 78.5 6.9 68.0 4.8a 705 6.8 70.8 5.9 8.0 0.5 13.1 1.0c
VLPD/EAA 81.0 4.4 70.3 72.5 4.4 71.3 3.7 8.5 0.7 14.1 l.2c
Abbreviations are: I, fasting; 2, feeding; VLPD, very low protein diet, supplemented with ketoacids (KA) or essential amino acids (EAA).
Measurements were performed between 11 and 12 a.m. (fasting) and 5 and 6 p.m. (feeding). Leucine turnover was calculated using plasma
a-ketoisocaproate specific radioactivity. Protein synthesis and degradation estimated as leucine incorporation or release from whole-body protein,
respectively. Rates of whole-body protein synthesis, degradation, and oxidation did not differ between the VLPD/KA or VLPDIEAA regimens.
Values are means SE.
a p < 0.01bP < 0.005
P < 0.001, fasting vs. feeding
indicate no such effect. Finally, a "carryover" effect from KA
seems improbable as the study included a 30 day "wash-out"
between treatment periods; (KA first; mean 65 days; range 38 to
84 days; EAA first; mean 57 days; range 39 to 95 days). More
importantly, a "carryover" effect would not explain the more
positive BN with KA during period 1.
The conservative interpretation we favor is that both diets
were nutritionally adequate and the reduction in urea nitrogen
appearance with KA reflected the lower overall nitrogen intake,
that is, the VLPD/KA and VLPD/EAA regimens provided 0.52
0.02 and 0.60 0.02 g protein/kg SBW/day, respectively
(0.55 0.03 vs. 0.64 0.03 g protein/kg actual body wt/day).
The ability of the VLPD/KA regimen to maintain neutral BN
despite a lower nitrogen intake would have a therapeutic
advantage in terms of limiting waste nitrogen accumulation in
patients with advanced renal failure. It should also be appreci-
ated that an intake of 0.52 to 0.55 g protein/kg/day is -l SD
below the mean requirement for normal subjects and CRF
patients (0.58 to 0.63 g protein/kg/day) [6, 46]. Moreover, some
question still remains as to whether the conventional low
protein diet providing 0.6 g protein/kg/day yields neutral BN in
CRF patients, at least during the short-term [7].
The leucine turnover measurements provide insight into the
adaptive responses which allowed these patients to achieve
nitrogen equilibrium while consuming the VLPD regimens.
First, rates of whole-body protein synthesis, degradation, and
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C
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Fig. 4. The expired '3C02 (A) and plasma [1-
'3CJ a-KIC (B) enrichments measured during
fasting and feeding in CRF patients
consuming the VLPD/KA (closed circles) or
VLPD/EAA (open circles) regimens. Values
are mean SE.
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Table 4. Plasma hormone concentrations measured in response to fasting and feeding during the leucine turnover protocol
Insulin MU/mI Glucag
1
on pg/mi
2
Cortiso1 g/di Growth hormone nglml
1 21 21 2
VLPD/KA 10.9 0.8 51.4 6.6a 345 41 630 67 7.2 0.5 7.6 0.6 1.7 0.4 1.3 0.2
VLPD/EAA 11,9 0.8 55.4 8.0 345 45 624 63 7,4 0.7 6.9 0.7 1.7 1.0 0.7 0.1
Abbreviations are in Table 3. Plasma hormone concentrations were measured between 11 and 12a.m. (fasting) and S and 6 p.m. (feeding). Values
are means SE.
a P < 0.001, fasting vs. feeding
Table 5. Plasma branched-chain amino acid concentrations measured in response to fasting and feeding during the leucine turnover protocol
Leucine Isoleucine Valine
1 2 1 2 1 2
i.imol/liter
VLPD/KA 99.2 4.7 90.6 6.5 46.0 3.5 36.1 33b
VLPD/EAA 99.1 5.2 93.0 7.Oa 47.0 2.8 37.3 2.6a
140.8 9.0 114.3 7.3
159.7 9.6 125.0 9.1'
Abbreviations are in Table 3. Plasma branched-chain amino acid concentrations were measured between
p.m. (feeding). Values are means SE.
a p < 0.01
b P < 0.005
P < 0.001, fasting vs. feedingd P < 0.05, KA vs. EAA, during feeding
11 and 12 a.m. (fasting) and 5 and 6
oxidation did not differ between the two VLPD regimens,
indicating that both KA and EAA invoke similar metabolic
responses (Table 3). Secondly, feeding decreased whole-body
protein degradation, whereas no significant change in protein
synthesis was noted. Thus, the primary anabolic response to
feeding was a reduction in proteolysis. The influence of feeding
on whole-body protein turnover during different nutritional and
metabolic states, was recently summarized by McNurlan and
Garlick [47]. Although there is general agreement that feeding
increases amino acid oxidation and decreases protein degrada-
tion, the majority of studies seem to indicate that protein
synthesis does not change [47]. Our results with the VLPD
regimen containing —0.3 g protein!kd/day plus KA or EAA, and
those of Goodship et a! [7], who measured protein turnover in
patients with CRF patients consuming 0.6 and 1.0 g protein/kg!
day, are consistent with this conclusion.
Of particular significance are the very low rates of leucine
oxidation during fasting, and the limited increase in response to
feeding either VLPD regimen. There are now a relatively large
number of reported estimates of leucine oxidation and flux rates
measured during the fasting state in healthy adult subjects. The
published values of leucine oxidation are variable, ranging from
about 13 to 39 pmol . kg' hr1 [7, 48], with the mean value
being about 18 smol kg1 hC' [7, 37, 48—57]. The fasting
leucine flux values also vary among the different studies, with
most reported values being above —90 pmol kg hr [7,
37, 49—52, 54—58], although some were less [48, 53]. The present
values for fasting leucine flux are —80 smol .kg hr' and
for leucine oxidation they were 8 to 8.5 mol . kg1 . hr1.
Thus, it would appear that our leucine oxidation rates are
considerably lower than essentially all other reported values,
and that the leucine flux values are also on the lower end of the
scale of published estimates for healthy adults.
We have also compared the rates of leucine oxidation mea-
sured during fasting and feeding in CRF patients consuming the
VLPD regimen (identified as 0.3 g), with rates measured when
CRF patients were eating 0.6 or 1.0 g protein/kg/day [7]. First,
as expected, feeding stimulates leucine oxidation with all three
dietary regimens (Fig. 5). Second, as dietary protein intake
increases, so do leucine oxidation rates. Third, rates of leucine
oxidation with the VLPD regimen are 50% to 100% lower when
compared to the values obtained when CRF patients consumed
0.6 or 1.0 g protein/kg/day.
There are at least two potential explanations for the low rates
of leucine oxidation compared to healthy subjects or CRF
patients consuming 0.6 g protein/kg/day. First, if the diet was
inadequate, then leucine oxidation rates during feeding might
decrease because of limited availability of leucine [59]. Since
the formula was designed to provide one-half the prescribed
daily intake of protein (excluding the supplement) or 0.14 g
protein/kg, this would correspond to an intake of 32.0 0.7 mg
leucine per kg ABW per day. This is approximately twice the
intake considered by the FAO/UNU/WHO as representing the
upper physiologic requirement for healthy adults [46], and
similar to recent estimates derived from leucine balance studies
[60]. Therefore, it seems unlikely that an inadequate leucine
intake can explain the low rates of leucine oxidation measured
during feeding. Moreover, this cannot explain the low values
measured during fasting. We suggest that a more likely expla-
nation for the low fasting leucine oxidation rates and limited
increase in response to feeding, is that branched-chain ketoacid
dehydrogenase activity (BCKAD) was down-regulated in re-
sponse to dietary protein restriction [61]. That amino acid
catabolism is modulated by the net intake of dietary protein is
also suggested by our finding that urinary protein losses in
nephrosis activate protein conservation by decreasing amino
acid oxidation [62]. The tissue(s) responsible for the reduction
in leucine oxidation in CRF patients consuming the VLPD
regimen, and whether this is due to alterations in transcription,
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Fig. 5. Depicted are the rates of leucine oxidation measured in CRF
patients consuming either the VLPD regimen (identified as 0.3), or
alternatively 0.6 or 1.0 g protein/kg/day. Leucine oxidation rates were
measured during fasting (open circles) and feeding (closed circles). The
leucine oxidation rates for the 0.6 or 1.0 g protein diets are derived from
the paper of Goodship et al [7]. Results are expressed as mean SE. By
ANOVA, feeding stimulates leucine oxidation during all three dietary
regimens (P < 0.001). § P < 0.005; compared to fasting leucine
oxidation value for 0.28 g protein/kg/day. 1 P < 0.001; compared to
feeding leucine oxidation value for 0.28 g protein/kg/day.
translation, or the activity state of BCKAD remains to be
determined [59].
Since leucine oxidation rates did not differ between the
VLPD/KA or EAA regimens, and the protein intake with EAA
was -'0.6 g protein/kg/day, an appropriate question is why
leucine oxidation was lower than reported in normal subjects or
CRF patients consuming the conventional LPD [7, 63]. Al-
though a definite answer cannot be provided, in the latter
studies leucine kinetics were measured —6 to 8 days following
dietary manipulation. In contrast, all participants in the current
study consumed a conventional LPD containing 0.6 g protein/
kg/day for at least one month before they were randomized to
the VLPD diet, and for an additional month during the "wash-
out" period between CRC admissions. Moreover, equilibration
to the VLPD regimen was assured by having the patients
initiate the diet two weeks prior to admission and by performing
the leucine turnover measurements on the final day of the
protocol (day 10). If this response does represent a true
adaptation, it would suggest that it may take several weeks
following dietary manipulation before a new steady state is
attained [641.
With the exception that postprandial plasma valine levels
were significantly higher with EAA, plasma branched-chain
amino acids (BCAA) concentrations did not differ between
dietary regimens (Table 5). In response to feeding, plasma
BCAA levels decreased modestly with both regimens. The
postprandial decrease in plasma BCAA concentrations could be
due to increased oxidation, decreased protein degradation,
increased incorporation into protein, or some combination of
the above. Supraphysiologic infusions of leucine have been
shown to decrease plasma valine and isoleucine levels [22, 25],
a finding initially attributed to activation of BCKAD by a-ke-
toisocaproate [65]. However, Nair, Schwartz and Welle [22]
recently reported that an infusion of leucine containing sixfold
more leucine than provided by our combined meal and intrave-
nous infusion (154 vs. 25 mol kg hr', respectively) did
not stimulate valine oxidation. Feeding did not stimulate whole-
body protein synthesis in our study, so increased incorporation
of amino acids into body protein cannot explain the decrease in
plasma BCAA levels. Therefore, in the absence of enhanced
protein synthesis or increased oxidation, the decrease in plasma
BCAA levels during feeding can only be explained by a reduc-
tion in protein degradation. It has been suggested that the
decrease in whole-body proteolysis following feeding is due to
the postprandial increase in insulin levels [41, 66].
We identified no differences in the plasma hormone concen-
1 0 trations (Table 4) between the VLPD/KA or EAA regimensduring fasting or feeding. As expected, plasma insulin and
glucagon levels increased with feeding, whereas plasma cortisol
and growth hormone levels did not change. When compared to
healthy subjects, fasting and postprandial glucagon levels were
increased in our patients, while plasma cortisol and growth
hormone levels were normal. Hyperglucagonemia is well rec-
ognized in patients with CRF and has been attributed to
impaired metabolic clearance [67, 68]. In contrast, growth
hormone levels have been reported to be normal or increased in
CRF [67, 69].
We also determined whether GFR was correlated with the
degree of abnormality in any of our nutritional measures. By
analysis of covariance (ANCOVA), there was no independent
effect of GFR on the measured nutritional indices between
diets.
In summary, this study indicates that a VLPD supplemented
with either KA or EAA should produce neutral nitrogen bal-
ance in most patients with CRF. Successful adaptation to the
VLPD regimen involved a marked reduction in amino acid
oxidation and a postprandial inhibition of protein degradation,
resulting in more efficient utilization of amino acids. Thus, the
adaptive responses to dietary protein restriction remains intact
in CRF patients consuming the VLPD regimen. Finally, evi-
dence indicating that a VLPD supplemented with KA slows
progression compared to an identical diet plus EAA [5], while
maintaining neutral BN despite a lower nitrogen content, sug-
gests a therapeutic advantage for KA over EAA in patients with
moderate to severe CRF.
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